Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intelgenx Technologies Corp IGXT

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.


GREY:IGXT - Post by User

Intelgenx Technologies Corp
Bullboard Posts
User Avatar Image
(0)
•••
Post by lanaar2on Jul 12, 2013 6:38pm
273 Views
Post# 21605360

Most recent analyst report

Most recent analyst reporthttps://www.thelifesciencesreport.com/cs/user/download/co_file/4163
From Aegis Capital.
What has me turned off is this paragraph from Q1 2013:

Royalty income in the second quarter of 2013 is expected to be lower than royalty income achieved in the current quarter, as a result

of lower than anticipated sales of Forfivo XL™ during the current quarter. Management is assessing this variation in sales

performance with a view towards taking steps to support steady sales growth of Forfivo XL™.



Given this information, Aegis is still predicting higher Q2 2013 sales of Forfivo. It does not jive with me.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities